Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Return on Sales (2020 - 2025)

Neuroone Medical Technologies' Return on Sales history spans 12 years, with the latest figure at 0.5% for Q4 2025.

  • For Q4 2025, Return on Sales fell 104.0% year-over-year to 0.5%; the TTM value through Dec 2025 reached 0.78%, up 47.0%, while the annual FY2025 figure was 0.4%, 317.0% up from the prior year.
  • Return on Sales reached 0.5% in Q4 2025 per NMTC's latest filing, up from 0.59% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.55% in Q4 2024 to a low of 131.25% in Q1 2021.
  • Average Return on Sales over 5 years is 29.45%, with a median of 6.53% recorded in 2023.
  • Peak YoY movement for Return on Sales: plummeted -5577bps in 2021, then skyrocketed 8060bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 83.19% in 2021, then soared by 82bps to 15.12% in 2022, then skyrocketed by 77bps to 3.42% in 2023, then soared by 116bps to 0.55% in 2024, then crashed by -191bps to 0.5% in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Return on Sales are 0.5% (Q4 2025), 0.59% (Q3 2025), and 0.88% (Q2 2025).